CN102727495A - Novel use of sanguinarine chloride - Google Patents
Novel use of sanguinarine chloride Download PDFInfo
- Publication number
- CN102727495A CN102727495A CN201110095475XA CN201110095475A CN102727495A CN 102727495 A CN102727495 A CN 102727495A CN 201110095475X A CN201110095475X A CN 201110095475XA CN 201110095475 A CN201110095475 A CN 201110095475A CN 102727495 A CN102727495 A CN 102727495A
- Authority
- CN
- China
- Prior art keywords
- sanguinarine
- cell
- hydrochloride
- thyroid carcinoma
- thyroid cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to a novel use of sanguinarine chloride and especially relates to a use of sanguinarine chloride in preparation of a drug for treating a thyroid cancer. In-vivo and in-vitro thyroid cancer experiments prove that sanguinarine chloride has effects of inhibiting or killing thyroid cancer cells, has human papilloma thyroid cancer cells IHH-4 and human anaplastic thyroid cancer cells ASH-3 growth IC50 values of 1.44 micromoles per liter and 2.62 micromoles per liter, and reduces a survival rate of thyroid cancer cells to less than 10%. A nude-mice in-vivo anti-cancer experiment proves that sanguinarine chloride has a transplantation tumor inhibition ratio of 80.81%.
Description
Technical field
The present invention relates to the medical usage field, be specifically related to the new purposes of Sanguinarine hydrochloride aspect preparation treatment cancer.
Background technology
Thyroid carcinoma (Thyroid cancer) is made up of the cancerous protuberance of several different biological behaviors and different pathological types, mainly comprises four types of papillary adenocarcinoma, folliculus shape cancer, undifferentiated carcinoma, medullary carcinoma.Their age of onset, the speed of growth, route of metastasis, prognosis are all obviously different, and like 10 years survival rates of papillary adenocarcinoma postoperative nearly 90%, and the undifferentiated carcinoma range is very short, generally only survives several months.
Thyroid carcinoma accounts for 1% of all cancers greatly, and in the popular district of endemicity nodular goiter, the sickness rate of the particularly low differentiation thyroid carcinoma of thyroid carcinoma is also very high.According to international cancer association statistics, the sickness rate of various countries' thyroid carcinoma increases year by year.China Shanghai City nineteen sixty sickness rate is to raise to 3.80/10 ten thousand in 1.02/10 ten thousand, 1978.According to Shanghai Medical Univ attached in mountain, Huashan hospital statistics, the Supreme People's Court and the Supreme People's Procuratorate accepts thyroid illness 6432 examples for medical treatment altogether in 1975-1985, thyroid tumor 4363 examples wherein, thyroid carcinoma accounts for 435 examples, is 10.1% of the whole tumors of thyroid.
Thyroid carcinoma is fallen ill more with the women, men and women's ratio 1: 2.58 in the age, can take place from child to old age per capita, but sends out in old people's characteristics differently well with general cancerous protuberance, and thyroid carcinoma is more to betide person between twenty and fifty, and its average age of onset is about 40 years old.
Because thyroid carcinoma has multiple different histological type and biological characteristics, therefore its clinical manifestation also has nothing in common with each other.It can exist with multiple thyroid nodule simultaneously, and is most asymptomatic, and there are a tuberosity or lump in accidental existing anterior region of neck, and the lump that has has existed for many years and just increased rapidly in the recent period or shifting.The patient who has does not have uncomfortable main tearing open for a long time, Cervical Lymph Node Metastasis, pathologisch Bruch, hoarseness, respiratory disorder, dysphagia even Horner syndrome occur to the later stage and just arouses attention.Local sign also is not quite similar, and asymmetric tuberosity of the thyroid of being or lump are arranged, and lump or in body of gland is with swallowing and up and down.When treating that surrounding tissue or trachea are invaded, lump is promptly fixing.
From pathology angle branch, thyroid carcinoma mainly contains following several kinds:
1, papillary adenocarcinoma:
Papillary adenocarcinoma is a modal type in the thyroid carcinoma, accounts for 70%.Not of uniform size.General well differentiated, grade malignancy is low.Cancerous tissue is crisp soft frangible, and color is dark red; But the strong cancer of gerontal patient's nipple is generally harder and pale.Often there is the cystis degeneration at the center of papillary carcinoma, is full of courageous and upright liquid in the capsule.Sometimes calcification can take place in cancerous tissue, and tangent plane is sand grains appearance.The grade malignancy of above-mentioned cystis degeneration and calcification and cancerous protuberance and prognosis are irrelevant.
Microscopically is seen: carcinoma is made up of the columnar epithelium papillae, can be mixed with the folliculus spline structure sometimes, even finds the situation of mamillary to the variation of folliculus appearance.The papillary adenocarcinoma leaf has complete peplos; Can wear out peplos equally and invade and surrounding tissue to the later stage, approach mainly is a lymphatic channel, and is generally common with Cervical Lymph Node Metastasis; Child about 80% and 2% adult patients can be laid one's hand on and lymph node, secondly are that blood transfer arrives lung or bone.
2, follicular adenocarcinoma:
Rare than papillary adenocarcinoma, account for 20% of thyroid carcinoma, occupy second, its patient's mean age is big than papillary carcinoma person.Cancerous protuberance is soft, tool elasticity, or rubber-like, rounded, ellipse or leaflet nodiform.Tangent plane is bronzing, visible fibrosis, calcification, hemorrhage and necrosis region.
WD follicular adenocarcinoma is the visible organizational structure similar with normal thyroid under mirror, but the affected phenomenon of peplos, blood vessel and lymphatic vessel is arranged; The follicular adenocarcinoma of poor differentiation is then seen irregular structure, and the intensive one-tenth bulk of cell or streak seldom forms folliculus.Though the approach of sending out can mainly be to lung, bone regulating liver-QI through blood transfer through lymph metastasis.Some follicular adenocarcinoma can be separated by behind excision and just be seen recurrence for a long time, but its prognosis is good not as good as papillary adenocarcinoma.
3, medullary thyroid carcinoma:
Account for 2～5% of thyroid carcinoma.This disease is at first described in nineteen fifty-nine by Hazard, has the characteristics of secretion thyrocalcitonin and occur together pheochromocytoma and thyroid gland hypertrophy (II type multiple endocrine neoplasm, MEN II).Medullary carcinoma is derived from thyroid embryo's the postbranchial body (ultimobranchial body), changes from the other bright cell (C cell) of folliculus.Parafollicular cell is the endocrine cell that derive from neural crest; These endocrine cell have a kind of common function; Can absorb precursors such as 5-hydroxy tryptamine and dopamine; And give decarboxylation through wherein decarboxylase, so be also referred to as amine precursor uptake and decarboxylation cell (amine precursor uptake and decarboxylation), be called for short APUD cell.Mostly tumor is the single-shot tuberosity, and idol has pilosity, and matter is fixed firmly, and amyloid deposition is arranged, and seldom absorbs radioiodine.The cancerous cell form mainly is made up of polygon and spindle cell, arranges variation.
4, anaplastic thyroid carcinoma:
Account for 5% of thyroid carcinoma, mainly betide patient above middle age, the male sees more.Lump matter is hard and irregular, and is fixing, and growth is filled the air very soon and involved thyroid rapidly, generally just can soak into trachea, muscle, nerve and blood vessel in a short time, causes and swallows and dyspnea.Tumor by local can have tenderness.
Microscopically sees that cancerous tissue mainly is made up of PD epithelial cell, and cell is pleomorphism, common karyokinesis phase.Lymphadenectasis can appear in cervical region, also has lung to shift.This disease poor prognosis, invalid to radioiodine therapy, local symptom is only controlled in external exposure.
In in the past several years, multiple new diagnosis and Therapeutic Method have appearred.Wherein, differentiation therapy is comparatively effective again for heavy dose of radioiodine therapy and Induced by Retinoic Acid.Although many DTC have a benign relatively course of disease, the treatment that the cancer patient of radioiodine ability is gathered in those forfeitures is still a difficult problem.
Sanguinarine (Sanguinarine, SAN), shown in II, different name is a pseudochelerythrine, and its CAS accession number is 2447-54-3, and molecular formula is C
20H
14NO
4, molecular weight is 332.Sanguinarine mainly is present in the herb of Herba Chelidonii, the tuber of Herba corydalis edulis, the herb of Herba Macleayae Cordatae, the aerial parts of Eomecon chionantha Hance.
Sanguinarine hydrochloride (Sanguinarine Chloride) is called Sanguinarium Chloride again, Oxysanguinarine, Sanguinarine chloride.Shown in I, the CAS accession number is 5578-73-4, and molecular formula is: C
20H
14ClNO
4, molecular weight: 367.78.
Because Sanguinarine pharmacological action has widely been used several centuries by the traditional medicine of the traditional Chinese medical science and North America.
Sanguinarine is used to treat various diseases as Chinese medicine usually, comprising following cancer:
Cancer of pancreas: Duke (1985) discovers that Sanguinarine has therapeutical effect for cancer of pancreas, evidence, and Sanguinarine can significantly suppress growth, the growth of pancreatic cancer cell AsPC-1 and BxPC-3, and the formation ability of bacterium colony; Haseeb Ahsan (2007) confirms that also Sanguinarine can reach the apoptosis of inducing human pancreatic cancer cell AsPC-1 and BxPC-3 through regulating the proteic approach of Bcl-2;
Human oral cavity epithelial cell carcinoma: Hang etc. (2007) research shows, through the exposure of 24h, compares with matched group, adds 2pM and 3pM Sanguinarine group and has shown the toxic action for KB cancerous cell (human oral cavity epithelial cell), and MTT is reduced to 83% and 52% respectively; The bacterium colony that Sanguinarine can also suppress the KB cancerous cell forms and energy for growth.In addition, add 2pM and 3uM Sanguinarine group and obviously show the apoptotic effect of KB of inducing;
Melanoma: the K1735-M2 cell is a MC, is considered to a good model of metastasis melanin tumor, and (2008) such as Teresa L are found, Sanguinarine can kill the K1735-M2 cell and hinder its propagation;
Breast carcinoma: (2006) such as Holy J prove that Sanguinarine suppresses breast carcinoma through the approach of the caryoplasm transportation of cracking MCF-7 cyclin;
Hepatocarcinoma: Huang Xinhui etc. (2001) test discovery, and Sanguinarine can suppress SMM C-7721 human liver cancer cell propagation, and HCC is had tangible lethal effect; The Sanguinarine that CN200810105012.5 discloses 5 μ g/ml is 98% to the suppression ratio of human liver cancer cell HEPG-2.
Report was once arranged, and ethoxysanguinarine (ethoxysanguinarine) has antibiotic preferably, antiinflammatory action, and is evident in efficacy to cervicitis especially.Cervical cancer, thyroid tumor etc. has also been shown certain curative effect.
At present, do not find the report that Sanguinarine hydrochloride is used both at home and abroad as yet in preparation treatment thyroid carcinoma medicine.
Summary of the invention
The object of the invention is to provide the new purposes of Sanguinarine hydrochloride.
Concrete, the invention provides the application of Sanguinarine hydrochloride in the medicine of preparation treatment thyroid carcinoma.
Preferably, thyroid tumor is papillary adenocarcinoma or undifferentiated thyroid carcinoma.
Said Sanguinarine hydrochloride when using, can be formed preparation with pharmaceutically acceptable carrier or diluent.
Said preparation is selected from regular dosage forms such as tablet, pill, capsule, drop pill, controlled release agent, microcapsule, liposome, suspensoid, Emulsion, injection, infusion solutions or lyophilized formulations.
Said pharmaceutically acceptable carrier or diluent are selected from one or more in starch, lactose, sucrose, mannitol, microcrystalline Cellulose, low-substituted hydroxypropyl cellulose, cross-linking sodium carboxymethyl cellulose, sodium chloride, glucose, hydroxypropyl methylcellulose, polyvinylpyrrolidone, magnesium stearate or the Pulvis Talci.
The present invention is applied to human dose and drafts and be about 0.01～1g/ day.
The invention has the advantages that:
1) the new purposes of Sanguinarine hydrochloride is provided, has expanded the treatment field of Sanguinarine hydrochloride;
2) products material of the present invention is originated and is enriched, and preparation technology is simple, can make conventional formulation, and is like tablet, capsule, injection etc., easy to use;
3) through the inside and outside antithyroid cancer test of body; Confirm these article external thyroid carcinoma cell is had suppress or killing action; IC50 to human papillary thyroid carcinoma cell IHH-4, people's undifferentiated thyroid carcinoma cell ASH-3 growth is respectively 1.44 μ mol/L, 2.62 μ mol/L, and the thyroid carcinoma cell survival rate is reduced to below 10%; In the experiment of nude mice vivo antitumor, Sanguinarine hydrochloride can reach 80.81% to the suppression ratio of transplanted tumor;
4) in the experiment of nude mice vivo antitumor, Sanguinarine hydrochloride can reach 80.81% to the suppression ratio of transplanted tumor;
5) effect experiment confirms simultaneously: the effect of the antithyroid cancer of Sanguinarine hydrochloride is superior to ethoxysanguinarine.
Description of drawings:
Fig. 1: 1.5 μ mol/L Sanguinarine hydrochlorides are handled the influence (n=6) of different time to IHH-4 cell and ASH-3 cell survival rate;
Fig. 2 variable concentrations Sanguinarine hydrochloride is handled the influence of back IHH-4 cell and the formation of ASH-3 cell clone, with the matched group ratio,
*P＜0.05.
The specific embodiment
Following examples are used to explain the present invention, but are not used for limiting scope of the present invention.Embodiment 1: the Sanguinarine hydrochloride sheet
1, prescription: Sanguinarine hydrochloride 30g, starch 60g, magnesium stearate 2g.
2, method for preparing: take by weighing supplementary material according to recipe quantity, according to the equivalent method mixing that progressively increases, direct compression is processed 1000.
3, usage and dosage: oral, each 1, every day 3 times.
Embodiment 2: the Sanguinarine hydrochloride capsule
1, prescription: Sanguinarine hydrochloride 30g, 10% hydroxypropyl methylcellulose 32ml (the 10%th, 10g/100ml).
2, method for preparing: take by weighing in supplementary material, granulation, granulate, 1000 capsules are processed in fill.
3, usage and dosage: oral, each 1, every day 3 times.
Embodiment 3: the Sanguinarine hydrochloride high-capacity injection
1, Sanguinarine hydrochloride 40mg, sodium chloride 2.25g processes the Sanguinarine hydrochloride sodium chloride injection, and its specification is 250ml;
Take by weighing supplementary material, add 100ml water for injection, fully stir and make dissolving, added 5-10g active carbon heated and boiled 15-30 minute, the medicinal liquid circulation is cooled to 40-50 ℃, decarbonization filtering; Regulate pH to 6.3-8.3, add the injection water to 250ml, fill, sterilization, lamp inspection promptly gets.
2, Sanguinarine hydrochloride 40mg, glucose 12.5g processes the Sanguinarine hydrochloride glucose injection, and its specification is 250ml:
Take by weighing supplementary material, add 100ml water for injection, fully stir and make dissolving, added 5-10g active carbon heated and boiled 15-30 minute, the medicinal liquid circulation is cooled to 40-50 ℃, decarbonization filtering; Regulate pH to 6.0-8.0, add the injection water to 250ml, fill, sterilization, lamp inspection promptly gets.
3, usage and dosage: intravenous injection, each 1 bottle, once a day.
Embodiment 4: the Sanguinarine hydrochloride injection
1, forms: the 20g of Sanguinarine hydrochloride 20g, water for injection, mannitol 3g.
2, method for preparing: get Sanguinarine hydrochloride 20g, add proper amount of water for injection, with sodium carbonate adjust pH to 7, stirring and dissolving; Add the mannitol that is equivalent to get Sanguinarine hydrochloride 10-15% amount injection again, degerming filters, and measures content, 1000 of packing; 20mg/ props up, and seals, and promptly gets.
3, usage and dosage: intravenous injection, each 40mg, once a day.
Below be the effect experiment research that Sanguinarine hydrochloride is carried out.
Embodiment 5: external anticancer experiment
Adopting active improvement mtt assay of cancer-resisting substance and PCR cloning PCR to measure cell clone forms.
1, material:
JEG-3: IHH-4: people's mamillary thyroid carcinoma cell; ASH-3: people's undifferentiated thyroid carcinoma.
Sanguinarine hydrochloride: adopt the medicine of embodiment 4 preparations, provide by the applicant;
Ethoxysanguinarine: available from standing grain bio tech ltd on the Changsha, 20mg/ props up.
2, cell culture:
IHH-4 cell line and ASH-3 cell line are used RPM I1640 culture medium and are carried out monolayer culture:
Add hyclone (FBS), 50U/mL penicillin and the 50U/mL streptomycin of 10% (v/v) in the culture medium; IHH-4 cell line that grows in exponential phase and ASH-3 cell line are digested through 0.25% pancreas enzyme-EDTA Digestive system; Harvesting; And be resuspended in the culture medium, the final concentration of cell is 1 * 10
5/ mL; (every hole 200 μ l) evenly are inoculated in the 96 porocyte culture plates with cell suspension, contain 5%CO at 37 ℃
2Environment cultivate down 24h.
3, mtt assay detects the influence of Sanguinarine hydrochloride to growth of cancer cells
3.1 the variable concentrations Sanguinarine hydrochloride is to the influence of growth of cancer cells at one time
Two kinds of cells add the Sanguinarine hydrochloride that concentration is respectively 0,0.1,0.5,0.75,1.0,1.5,2.0,2.5 and 5.0 μ mol/l respectively, and compare with 5.0 μ mol/l ethoxysanguinarines.Each concentration is established 6 multiple holes.After cell continue to be cultivated 24h, adding 20 μ l concentration was the MTT of 5mg/ml then, sopped up culture medium gently after cultivating 4h again.Add 100 μ l DMSO, vibration dissolving 10min.On ELIASA, choose the 570nm wavelength and measure absorbance, the cellular control unit survival rate is made as 100%, and all the other respectively organize cell survival rate=(each concentration group absorbance/matched group absorbance) * 100%.
3.2 same concentration Sanguinarine hydrochloride is in the influence of different time cell growth
After the same method of cell is cultivated 24h, behind the Sanguinarine hydrochloride that adds 1.5 μ mol/l and the ethoxysanguinarine respectively at 12,24,36,48 with measure cell survival rate during 60h, described in other experimental procedures same 3.1.
4, clone forming method detects cell survival rate
Exponential phase cell preparation single cell suspension, adjustment cell concentration to 1 * 10
6Individual/ml, IHH-4 cell and ASH-3 cell are inoculated in respectively in the culture dish that diameter is 60mm, add the Sanguinarine hydrochloride of 0,0.1,0.5,1.0,2.0 and 3.0 μ mol/l behind the cultivation 24h, each concentration is established 3 multiple holes.Prepare single cell suspension with trypsinization after continue cultivating 24h, be seeded to the culture dish of 60mm with 500 cell/wares, each stoichiometric point is established 3 parallel appearance, cultivates 14d after PBS rinsing, methanol are fixed, Gimsa dyes.At the microscopically counting, contain the above cell colony of 50 cells as clone's counting.
5, statistical procedures
All experiments all repeat more than 3 times, and the result all representes with
.Adopt SPSS 13.0 statistical softwares to carry out statistical analysis; Relatively adopt variance analysis between group.
6, experimental result (seeing table 1 and Fig. 1,2):
6.1 the variable concentrations Sanguinarine hydrochloride is to the influence of IHH-4 cell and ASH-3 cell growth: the result sees table 1, Fig. 1.
Table 1: Sanguinarine hydrochloride is handled the influence
of 24h to IHH-4 cell and the growth of ASH-3 cell
(0 μ mol/L) compares with matched group,
△P＜0.05,
△ △P＜0.01,
△ △ △P＜0.001; Compare with ethoxysanguinarine,
#P＜0.05,
##P＜0.01.
Can find out from table 1: with matched group is that the concentration of Sanguinarine hydrochloride is that 0 μ mol/L compares, and the variable concentrations Sanguinarine hydrochloride demonstrates obvious suppression effect (P＜0.05, P＜0.01, P＜0.001) to thyroid carcinoma cell; Compare with ethoxysanguinarine, when the concentration of Sanguinarine hydrochloride was 5.0,2.5,2.0 μ mol/L, effect had evident difference (P＜0.05, P＜0.01) to the IHH-4 cell inhibiting; When the concentration of Sanguinarine hydrochloride is 5.0,2.5 μ mol/L, the inhibitory action of ASH-3 had evident difference (P＜0.01, P＜0.05).
By IHH-4, ASH-3 cell survival rate regression Calculation half-inhibition concentration (IC50) is 1.44 μ mol/L, 2.62 μ mol/L.
As can beappreciated from fig. 1: the Sanguinarine hydrochloride of variable concentrations is obviously different to the influence of IHH-4 cell and ASH-3 number of cell clones, and concentration is high more, and to kill the effect of cancerous cell strong more.
6.2 same concentration Sanguinarine hydrochloride is in the influence of different time cell growth
As can beappreciated from fig. 2: along with the prolongation of time, Sanguinarine hydrochloride is obvious dependence to the killing action of people's mamillary thyroid carcinoma cell and people's undifferentiated thyroid carcinoma.
7, experiment brief summary: experiment in vitro shows that Sanguinarine hydrochloride has obvious killing action to thyroid carcinoma cell, action intensity and dosage and time correlation.
Embodiment 6: to the influence of nude mice thyroid transplantation tumor
1, material
JEG-3: IHH-4, people's mamillary thyroid carcinoma cell;
Sanguinarine hydrochloride: the medicine that adopts embodiment 4 preparations;
Ethoxysanguinarine reference substance (98.0%): available from standing grain bio tech ltd on the Changsha, 20mg/ props up;
Cyclophosphamide for injection (CTX): available from Hengrui Medicine Co., Ltd., Jiangsu Prov., 100mg/ props up.
2, animal model is set up
Animal is prepared: five ages in week female nude mice (strain: BALB/c), body weight 18-20g, the Experimental Animal Center SPF of Jilin University level Animal Lab. is raised.Give the feedstuff and the water of sterilization treatment, adaptability is raised a week, and observes the whole body situation, confirms that nude mice is healthy.
Animal inoculation:
1) with the thyroid papillary carcinoma IHH-4 cell 0.1ml about 5 * 10 of exponential phase
5The individual pleurobranch portion of planting in the nude mice right side is subcutaneous.
2) there is scleroma at the plantation position behind the 7d, and the 14d tumor grows up to, and the about 0.65cm of the average major diameter of tumor begins experiment.
3) divide into groups:
At random nude mice is divided into Sanguinarine high dose group (10mg/kg), middle dose groups (3mg/kg), low dose group (1mg/kg) by the tumor size, ethoxysanguinarine group (10mg/kg), positive control CTX organize (30mg/kg) and negative control group (being model group).Every group 10.
4) handle:
Sanguinarine hydrochloride and ethoxysanguinarine, positive controls are respective concentration with physiological saline solution and dilution.
(1) treatment group gives the 50ul Sanguinarine and irritates stomach, once a day, and totally 5 weeks;
(2) the negative control group nude mice is accepted equivalent (50ul) blank solvent and irritates stomach and handle, once a day, and totally 5 weeks;
(3) measure the nude mice body weight weekly;
The back sacrifice of animal dissection of (4) five weeks, complete taking-up tumor tissues is weighed;
(5) inhibition rate of tumor growth (tumour inhibiting rate)=(W matched group-W treatment group)/W matched group * 100%.
3, statistical method:
Statistical result is all represented with
.Adopt SPSS 13.0 statistical softwares to carry out statistical analysis, relatively adopt variance analysis between group.
4, experimental result is seen table 2:
Table 2. Sanguinarine hydrochloride solution gastric infusion is to the clinical trial
of nude mice IHH-4 transplanted tumor
With the negative control group ratio,
*P＜0.05,
*P＜0.01,
* *P＜0.001; With ethoxysanguinarine group ratio,
△P＜0.05.
Can find out from table 2: compare with negative control group, each dose groups of CTX, ethoxysanguinarine and Sanguinarine hydrochloride all has tumor-inhibiting action in various degree to transplanted tumor in nude mice; Compare with the ethoxysanguinarine group, Sanguinarine hydrochloride is high, middle dose groups tumor-inhibiting action obviously is superior to ethoxysanguinarine (P＜0.05).
The experiment brief summary: experiment shows that Sanguinarine hydrochloride has good tumor-inhibiting action to transplanted tumor in nude mice in the body, and action intensity is relevant with dosage.
Conclusion: prove that through experiment in vivo and vitro Sanguinarine hydrochloride has remarkable inhibition or lethal effect to thyroid carcinoma, its action intensity is relevant with dosage and action time.
Though, used general explanation, the specific embodiment and test in the preceding text, the present invention has been done detailed description, on basis of the present invention, can to some modifications of do or improvement, this will be apparent to those skilled in the art.Therefore, these modifications or the improvement on the basis of not departing from spirit of the present invention, made all belong to the scope that requirement of the present invention is protected.
Claims (5)
1. the application of Sanguinarine hydrochloride in the medicine of preparation treatment thyroid carcinoma.
2. application according to claim 1, this thyroid carcinoma are papillary adenocarcinoma or undifferentiated thyroid carcinoma.
3. application according to claim 1 and 2 is characterized in that said Sanguinarine hydrochloride is the preparation of forming with pharmaceutically acceptable carrier or diluent.
4. application according to claim 3 is characterized in that said preparation is selected from tablet, pill, capsule, drop pill, controlled release agent, microcapsule, liposome, suspensoid, Emulsion, injection, infusion solutions or lyophilized formulations.
5. application according to claim 3 is characterized in that said pharmaceutically acceptable carrier or diluent are selected from one or more in starch, lactose, sucrose, mannitol, microcrystalline Cellulose, low-substituted hydroxypropyl cellulose, cross-linking sodium carboxymethyl cellulose, sodium chloride, glucose, hydroxypropyl methylcellulose, polyvinylpyrrolidone, magnesium stearate or the Pulvis Talci.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110095475XA CN102727495A (en) | 2011-04-15 | 2011-04-15 | Novel use of sanguinarine chloride |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110095475XA CN102727495A (en) | 2011-04-15 | 2011-04-15 | Novel use of sanguinarine chloride |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102727495A true CN102727495A (en) | 2012-10-17 |
Family
ID=46984265
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201110095475XA Pending CN102727495A (en) | 2011-04-15 | 2011-04-15 | Novel use of sanguinarine chloride |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102727495A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111920813A (en) * | 2020-09-30 | 2020-11-13 | 郑州大学 | Application of 6-ethoxy sanguinarine in preparation of antitumor drugs |
| CN113666790A (en) * | 2021-08-12 | 2021-11-19 | 遵义医科大学珠海校区 | Application of sanguinarine in preparation of jack bean urease inhibitor |
| CN114522165A (en) * | 2022-01-21 | 2022-05-24 | 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) | Application of sanguinarine chloride in preparation of medicine or health product for treating liver injury caused by arsenic |
| CN114533734A (en) * | 2022-03-22 | 2022-05-27 | 广东医科大学 | Application of sanguinarine in preparation of RIPK3 activator |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101904849A (en) * | 2010-08-19 | 2010-12-08 | 苏州大学 | Application of sanguinarine for preparing tumour radiotherapy sensitized medicine |
-
2011
- 2011-04-15 CN CN201110095475XA patent/CN102727495A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101904849A (en) * | 2010-08-19 | 2010-12-08 | 苏州大学 | Application of sanguinarine for preparing tumour radiotherapy sensitized medicine |
Non-Patent Citations (2)
| Title |
|---|
| 刘靖 等: "博落回生物碱的研究进展", 《广东饲料》, vol. 18, no. 4, 30 April 2009 (2009-04-30), pages 28 - 30 * |
| 欧阳丽 等: "分散液膜分离提取博落回中生物碱研究", 《第十七届全国色谱学术报告会议文集》, 19 April 2009 (2009-04-19), pages 142 - 143 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111920813A (en) * | 2020-09-30 | 2020-11-13 | 郑州大学 | Application of 6-ethoxy sanguinarine in preparation of antitumor drugs |
| CN113666790A (en) * | 2021-08-12 | 2021-11-19 | 遵义医科大学珠海校区 | Application of sanguinarine in preparation of jack bean urease inhibitor |
| CN114522165A (en) * | 2022-01-21 | 2022-05-24 | 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) | Application of sanguinarine chloride in preparation of medicine or health product for treating liver injury caused by arsenic |
| CN114533734A (en) * | 2022-03-22 | 2022-05-27 | 广东医科大学 | Application of sanguinarine in preparation of RIPK3 activator |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2871381T3 (en) | Composition to prevent and treat cancer-related fatigue, containing processed ginseng powder or processed ginseng extract that has an enhanced ginsenoside component | |
| CN109718208B (en) | Application of polysaccharide modified nano-selenium compound in malignant ascites treatment drug | |
| CN110013481A (en) | Maleic acid datro application in preparation of anti-tumor drugs | |
| CN105769891A (en) | Low-polarity rare ginsenoside mixture and application thereof | |
| CN102727495A (en) | Novel use of sanguinarine chloride | |
| CN1305513C (en) | Broad-spectrum cancer-treating Chinese medicine prepn and its prepn process | |
| CN102240353A (en) | Traditional Chinese drug anesthetic and preparation method thereof | |
| CN106039011A (en) | Traditional Chinese medicine for treating esophagus cancer and preparation method and application thereof | |
| CN103202861A (en) | Application of composition of clostridium butyricum and bifidobacterium dual live bacteria preparation and anticancer medicament in preparation of medicament for treating intestinal cancer | |
| CN103520649B (en) | The Chinese medicine for the treatment of facial neuritis | |
| US20200030401A1 (en) | Anticancer pharmaceutical composition and application thereof | |
| CN104189690A (en) | Traditional Chinese medicine preparation for relieving male prostatitis symptoms and proliferation | |
| CN110290787A (en) | For inhibiting the transfer of cancer and treating the composition of cancer | |
| CN100531791C (en) | Antineoplastic, anti-cancer drugs | |
| CN101019923A (en) | Anticancer medicine and its prepn | |
| CN110354121A (en) | Application of the Ciclopirox Olamine in preparation tumor and composition of medicine and purposes comprising Ciclopirox Olamine | |
| CN101797242A (en) | Application of cysteamine in preparing medicine for treating cancer | |
| CN109289022A (en) | A kind of pharmaceutical formulation inhibiting Colon and rectum adenoma | |
| CN103432282A (en) | Compound medicine for treating tumor | |
| CN109793726A (en) | Benzethonium chloride is preparing the application in the drug for preventing and treating lung cancer | |
| CN101199507B (en) | Application of furan diene and derivatives in preparing therapeautic cancer medicament | |
| CN102688240A (en) | Pharmaceutical composition for treating colorectal cancer | |
| CN101744802A (en) | Novel application of hydroxysafflor yellow A to preparation of anti-tumour drugs | |
| CN102406841A (en) | Traditional Chinese medicine for treating tumors | |
| US10953063B2 (en) | Method of treating select cancers using timed administration of plant extract from species Physalis pubescens and Hedyotis diffusa willd |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20121017 |